

Date: 28.05.2023

To

**Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Subject: Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of presentation made to analysts and investors in connection with Audited Standalone & Consolidated Financial Results for quarter & financial year ended 31st March, 2023.

You are requested to take the information on record and oblige.

Thanking You

Yours Faithfully,

For Natural Capsules Limited

SHILPA Digitally signed by
SHILPA BURMAN
Date: 2023.05.28
15:26:30 +05'30'
BURMAN

Shilpa Burman
Company Secretary & Compliance Officer





Investor Presentation

BSE: 524654

MAY, 2023

Safe Harbor

Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward -looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward - looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward - looking statements only speak as at the date the presentation is provided to the recipient and NCL is not under any obligation to update or revise such forward - looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipient’s purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and Laxmi has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.



Inside this document

01
QUARTERLY
HIGHLIGHTS

02
COMPANY
OVERVIEW

03
BUSINESS
CANVAS

04
SUSTAINABILITY

05
FINANCIAL
PERFORMANCE

06
INVESTMENT
MERITS

naturalcapsules.com

Quarterly Highlights

Quarterly Updates – Q4FY23 (Consolidated)

REVENUES **37.62 cr**

⬇️ -17.32% Q-o-Q

⬇️ -9.46% Y-o-Y

EBITDA MARGINS **17.65%**

⬇️ -358 BPS Q-o-Q

⬇️ -194 BPS Y-o-Y

EPS **₹ 2.80**

⬇️ -50.70% Q-o-Q

⬇️ -60.11% Y-o-Y

EBITDA **6.64 cr**

⬇️ -31.26% Q-o-Q

⬇️ -18.43% Y-o-Y

PAT **2.66 cr**

⬇️ -49.33% Q-o-Q

⬇️ -48.05% Y-o-Y



Management Commentary



We recently signed an exclusive distribution agreement with a multi-billion-dollar corporation for our capsules in the Mexico market.

Sunil Mundra

MANAGING DIRECTOR
NATURAL CAPSULES LIMITED



"I am delighted to provide you with an update on Natural Capsules Limited's performance in Q4FY23. Despite the challenging operating environment in the domestic pharmaceutical industry, we have managed to maintain our volumes without experiencing any declines. We believe that the period of declining realisations is behind us, as evidenced by a gradual rebound in realisations in Q1 and our anticipation of further increases throughout the year.

In terms of positive developments, we recently signed an exclusive distribution agreement with a multi-billion-dollar corporation for our capsules in the Mexico market. This presents a significant opportunity for us, considering Mexico's high import of capsules. Sales recognition from this contract is expected to commence in Q2 of the current financial year. Additionally, we are making progress in setting up HPMC lines, with the integration process of the first line currently underway. We anticipate the remaining two lines to be operational in Q2 and Q3 of FY24, respectively.

On the API front, we are pleased to announce that we expect to start selling small commercial batches from Q2, gradually increasing production from Q3. However, this necessitates a revision of our earlier guidance of achieving 50% capacity utilisation in the first year, as commercial sales will only commence from Q2FY24 and gradually ramp up from Q3FY24.

With respect to the Production Linked Incentive (PLI) program, we have received government approvals and have decided to opt for the PLI incentive from FY25. This strategic decision is based on the PLI being determined by sales quantity. We are reasonably confident that our volumes in FY25 will significantly surpass those of FY24, ensuring higher incentives. Additionally, the removal of the condition mandating a minimum 90% capacity utilisation for eligibility to receive the incentives is a positive development. Now, the incentives will apply to any quantity manufactured and sold.

Looking ahead to the upcoming financial year, we remain excited about our growth trajectory in both our business verticals. The commencement of the HPMC lines is expected to drive top-line growth and improve the margin profile of our capsules business. For our API business, our focus will be on rapidly ramping up operations."

CAPEX Tracker

Natural Capsules is geared to make significant capital expenditures in the quarters to come and is on track with its capsule business. The Company will focus on ramping up its endeavours in its API business in the coming quarters.

	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24
CAPSULES	<ul style="list-style-type: none"> Added 1 line for gelatin capsules added in June 	<ul style="list-style-type: none"> 1 line for gelatin capsules added in September 			<ul style="list-style-type: none"> 1 lines for HPMC capsules to be added in Q1FY24 	<ul style="list-style-type: none"> 1 lines for HPMC capsules to be added in Q2FY24 	<ul style="list-style-type: none"> 1 lines for HPMC capsules to be added in Q3FY24
API						<ul style="list-style-type: none"> Start of Commercial production in small batches 	

Upcoming API Plant



Profit & Loss Statement Summary (Consolidated)

PARTICULARS (₹ IN CRORES)	Q4FY22	Q3FY23	Q4FY23	FY22	FY23
Revenue from Operations	41.55	45.5	37.62	135.07	172.37
Other Income	0.81	0.05	0.21	1.01	0.57
Total Income	42.36	45.56	37.83	136.08	172.94
Total Operating Expenses	33.41	35.84	30.98	109.69	137.33
EBITDA	8.14	9.66	6.64	25.38	35.04
EBITDA Margins	19.59%	21.23%	17.65%	18.79%	20.33%
Finance Cost	0.67	0.95	1.12	1.96	3.41
Depreciation	1.4	1.74	1.87	5.04	7.21
Profit Before Tax and Exceptional Items	6.88	7.02	3.86	19.39	24.99
Profit After Tax	5.12	5.25	2.66	13.91	18.45
EPS	7.02	5.68	2.80	19.56	19.82

naturalcapsules.com

Company Overview



Introducing Natural Capsules Limited (NCL)

Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limited Company in 1993 at Bangalore, and it further expanded its operations to Pondicherry in 2003. The company is now foraying into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.

NCL prides itself on its abilities to provide turnkey solutions to all its customers.



VISION

To become the global leader for supply of capsules, providing impeccable services all across the globe.



MISSION

- To consistently innovate and manufacture products key to market's and customer's expectation
- To consistently provide highest quality products to its customers across the globe
- To become an integrated enterprise of global distinction

1994

Listed on BSE

150

Customers

259

Team Members

02

Manufacturing Units

18.0 BCPA*

Capacity in Q4FY23


21.91%

Exports Revenue in FY23

* BCPA – Billion Capsules per Annum

Our Journey

1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION



* BCPA – Billion Capsules per Annum | MCPD – Million Capsules per Day

Our Journey (contd.)

2015 – 2018: THE HURDLES WE FACED ON THE WAY

2015 – 18

- Fall in oil and commodity prices led to economic slowdown in African countries and caused a decline in export of pharmaceutical products and capsules from India. This led to a drop in demand for our products, which were selling well in Africa earlier. The selling prices gradually decreased as well, leading to drop in margins over a period of 3 years (FY16-FY18). NCL's strategy of focusing on exports proved to be counterproductive, during this period.
- NCL was quick to refocus on domestic markets, but soon demonetization and the implementation of GST in India caused disruption in the domestic pharmaceuticals industry, which led to bouts of severe drop in demand.

2019 ONWARD: THE BEGINNING OF A NEW AND IMPROVED NCL

2019 ONWARD

- 2019 onward NCL witnessed an increase in demand in both domestic and export markets, which led to improvement in margins.
- NCL also upgraded one of its capsule manufacturing lines to produce 2.5 MCPD (from its earlier capacity of 1.0 MCPD).
- The company's continued focus on R&D, in collaboration with other partners, led it to invent a new generation of capsule manufacturing technology as well.
- NCL replaced one of its old machines at Bangalore and installed its first new generation machine producing 4.8-5.0 MCPD (instead of the earlier capacity of 1 MCPD). The new generation machines are the fastest machines to manufacture capsules globally.

GOING FORWARD

Installed capacity as at Q4FY23 stands at **18 BCPA**

Three new generation machines to be commissioned by **Q3FY24** which will enhance installed capacity to **22 BCPA***

* Adjusted capacity for three HPMC lines

Product Offerings

Natural Capsules Limited manufactures a vast array capsules, including vegetarian capsules which they have pioneered in India.

The company is now foraying into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.



CAPSULES

- Hard Gelatin Capsules shells
- Hard Cellulose Capsules shells
- Others
 - Special Characteristic Variants
 - Shiny Capsules
 - Sweet Capsules
 - Fast Release Capsules
 - Regulatory Variants
 - SLS free Capsules
 - Preservative free Capsules
 - TSE free Capsules



APIs


Key steroidal API products

- Prednisolone & Derivative Salts
- Betamethasone & Derivative Salts
- Dexamethasone & Derivative Salts
- Hydrocortisone & Derivative Salts

Global Presence

Natural Capsules exports to 30 countries across 5 continents, bringing in sizable revenue from its export.

% OF EXPORT SALES



AFRICA

- Algeria
- Egypt
- Ghana
- Kenya
- Nigeria
- South Africa
- Sudan
- Tanzania
- Tunisia
- Uganda
- Zimbabwe

ASIA

- Bangladesh
- Bhutan
- Hongkong
- Nepal
- Oman
- Phillipines
- Sri Lanka
- Syria
- Thailand

CIS

- Georgia
- Uzbekistan
- Turkey

MIDDLE EAST

- Iran
- Iraq
- Kuwait
- UAE

SOUTH AMERICA

- Brazil
- Ecuador
- Peru

NORTH AMERICA

- Canada
- Mexico

Serving Leading Brands

With over 3 decades of experience in the pharma sector, NCL has garnered excellent relationship with customers across 30 countries. The company is now focused on acquiring customers who deal with regulated markets.

MARQUEE CUSTOMERS

	 A new way for a new world	 MICRO LABS LIMITED
		 aianta pharma limited
		 Live Long, Live Healthy.
	 Kopran	
 Vivimed		
 SUCCESS THROUGH INNOVATION	 Marksans Pharma Ltd. Health Care in Safe Hands	

CUSTOMERS FOR MORE THAN
10 YEARS

15%
of total customers

CUSTOMERS FOR MORE THAN
5 YEARS

22%
of total customers

REPEAT BUSINESS DURING
FY 23

81%
of total turnover

NEW BUSINESS DURING FY 23

19%
of total turnover

Board of Directors



Mr. Laxminarayan Mundra
WHOLE TIME DIRECTOR



Mr. Satyanarayana Mundra
WHOLE TIME DIRECTOR



Mr. Sushil Kumar Mundra
DIRECTOR



Mr. Sunil Mundra
MANAGING DIRECTOR



Mr. Pramod Kasat
INDEPENDENT DIRECTOR



Mr. C P Rangachar
CHAIRMAN & INDEPENDENT
DIRECTOR



Mr. S G Belapure
INDEPENDENT DIRECTOR



Mrs. Jyothi Mundra
DIRECTOR

naturalcapsules.com

02

Business Canvas




Capsules Segment



With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are exported to regulated and unregulated markets across the globe, following stringent applicable rules and regulations.


REVENUES & EBITDA MARGINS

(IN ₹ CRORE & %)



CAPACITY & CAPACITY UTILISATIONS

(IN BCPA & %)



MANUFACTURING FACILITIES APPROVED BY



2nd largest

Indian manufacturer of gelatin capsule

2 manufacturing

Facilities at Bengaluru and Pondicherry

18.0 BCPA

Capsules per annum manufacturing capacity as at Q4FY23

1st manufacturer

Of vegetarian capsules in India

Enhancing Capacities




- New machines developed in **technical collaboration DBDS Robotics Private Limited**
- The new machines installed will be the **fastest available machine** to manufacture hard capsules

Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets.

CAPSULES MANUFACTURING CAPACITY

(IN BILLIONS)



The ability to deliver faster will help Company to **attract large volume customers** and yield better margins by optimizing manufacturing cost per unit

₹ 38 Crores planned capital expenditure for enhancing capacity to 22.0 Bn capsules per annum

Brownfield capex by adding new machines at Bengaluru facility

Project funded through a mix of debt and equity

- ₹ 18 Crores bank borrowings &
- ₹ 20 Crores from internal accruals

~3x asset turns from incremental capacities at optimum capacity utilisation

Q3FY24 expected commercialisation of all incremental capacities of HPMC lines

Incremental capacities will be targeted towards **large volume pharmaceutical customers and new export markets**

API Segment



Natural Capsules Limited is now foraying into the API business segment through its subsidiary - Natural Biogenex Private Limited (NBPL) incorporated in 2020. The APIs that will be manufactured are,Hydrocortisone, Prednisolone, Betamethasone and Dexamethasone and their derivatives.

KEY DEVELOPMENTS

AUG 2018	JUL 2019	OCT 2019	AUG 2020	FEB 2021	MARCH 2023
					Ongoing installation of machines in fermentation and synthesis block and completion of Kilo Lab installation
				Awarded Three PLI applications for Dexamethasone, Betamethasone and Prednisolone.	
	<ul style="list-style-type: none"> Achieved lab scale production of hydro cortisone from 9OHAD. Started second fermentation for manufacture of Prednisolone. 	<ul style="list-style-type: none"> Filed patent for innovative process for manufacture of 9OHAD 	<ul style="list-style-type: none"> Achieved process improvements over existing knowhow in respect of effluent and de-foaming agents. Obtained Test Drug Licenses for Steroidal APIs. 		
Started R&D center to validate fermentation and synthesis technology to manufacture steroidal APIs using unique microbe.					

Greenfield Capex at Tumkur, spread across 5 acres

1st integrated facility in India for manufacturing of Steroidal API's using fermentation and synthesis chain of reactions

Facilities are being set up in compliance with WHO GMP (Geneva), USFDA and EU GMP certification guidelines

Zero Liquid Discharge manufacturing facility

3 approvals for steroidal API's under the PLI scheme of Government of India for bulk drugs

API Segment (contd.)

INR 130 Crores - planned capital expenditure for setting up the facility

~ **2x asset turns** from incremental capacities at optimum capacity utilisation

Project funded through a mix of debt and equity

- INR 48 Crores bank borrowings
- INR 20 Crores infused from Natural Capsules Limited
- INR 25 crores from fund raised from HNI investors
- INR 50 crores from Private Equity

Commercial production to begin by Q2FY24

THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME

DEXAMETHASONE

10 MT
Planned Capacity

11 MT
Imports to India in FY23
worth ~ ₹51 crores

- NCL will be the **only manufacturer** of this product in India

BETAMETHASONE

12 MT
Planned Capacity

25 MT
Imports to India in FY23
worth ~ ₹162 crores

- NCL will be the **only manufacturer** of this product in India

PREDNISOLONE

15 MT
Planned Capacity

40 MT
Imports to India in FY23
worth ~ ₹186 crores

- NCL will be **one of the two manufacturers** of this product in India

Efforts will be focused on catering to the domestic demand by substituting the imported inputs.

Production Linked Incentive (PLI) Scheme

With a view to attain self-reliance and reduce import dependence in critical APIs, a scheme called "Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and active Pharmaceutical Ingredients (APIs) In India" has been approved by the Government of India on 20th March, 2020.



- The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India's import dependence in critical APIs.



- A committee on drug security constituted by the Department of Pharmaceuticals collated the details of APIs imported in the country and identified 53 APIs for which the country is heavily dependent on imports.



- The scheme categorises four target segments covering 41 products.
- The 3 products to be manufactured by NCL fall under the 2nd category of Fermentation based niche KSMs/ Drug Intermediates / APIs



- Financial incentive under the scheme shall be provided on sales of identified products for six (06) years:
- For fermentation-based products, incentive for FY 25 to FY 28 would be 20%, incentive for 29 would be 15% and incentive for FY30 would be 10%.



The Company expects to receive an incentive amounting to

~ ₹67 Crores
over

the course of 6 years, which effectively de-risks the Company's investments significantly


Focus on R&D



NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company's recent entry into the API business is a testament to its firm belief in R&D.

R&D SPENDS & R&D AS A % OF REVENUE

(IN ₹ CRORE & %)



■ R&D spends ● R&D as a % of revenue

KEY AREAS OF RESEARCH

-  • New product development for steroidal and hormonal range of API's
-  • Process improvements for enhancing yields
-  • Development of new process for manufacturing existing products

2 DSIR

Recognised state of the art R&D facilities

15

Team members focusing on product innovations and product yield efficiencies

1 patent

Granted, 2 patents under approval, 1 patent under filing - as a result of strong innovation in technology and manufacturing processes

Team

Is qualified and experienced in scaling up steroidal APIs to commercial scale

ESOPs

have been issued to senior members of R&D team to align the long-term interests

naturalcapsules.com

03

Sustainability



Sustainability Initiatives



NCL believes in contributing towards environment and social improvement.

In its three decades of existence, the Company has engaged in multiple efforts to become more green and sustainable. NCL has also contributed significantly to the development of the people from around the Company's manufacturing sites.



SUSTAINABLE SITES

- Zero discharge facilities
- Solar power generation
- Solar concentrated heat generation funded by IREDA and 1st company to receive UNIDO grant for patented solar concentrated heat generation dishes in India



SUSTAINABLE PRODUCT PORTFOLIO

- Recycling of own waste for manufacturing gelatine capsules
- Recycling of water from effluent treatment plant



SUSTAINABLE COMMUNITIES

- COVID-19 relief work at Pitchaveerampet, Pondicherry (food and medicine distribution) and Attibele, Bangalore (medicine distribution)
- Undertook infrastructure work in nearby communities, such as building a community temple

naturalcapsules.com

04

Financial Performance

The background features a close-up, slightly blurred view of several blister packs containing capsules. The capsules are two-toned, with one end being a light color and the other being a darker color. The entire image is overlaid with a semi-transparent green filter. In the top left corner, there is a large, semi-transparent number '04'. The text 'naturalcapsules.com' is positioned in the upper left area. The main title 'Financial Performance' is written in a large, white, sans-serif font, with 'Financial' on the top line and 'Performance' on the bottom line, both partially overlapping the green circular area.

Profit & Loss Statement Summary (Consolidated)

PARTICULARS (₹ IN CRORES)	FY19	FY20	FY21	FY22	FY23
Revenue from Operations	59.78	61.55	79.51	135.07	172.37
Other Income	1.13	0.95	0.73	1.01	0.57
Total Income	60.91	62.50	80.24	136.08	172.94
Total Operating Expenses	54.89	56.25	68.58	109.69	137.33
EBITDA (excl. Other Income)	6.02	6.25	10.93	25.38	35.04
EBITDA Margins	9.88%	10.00%	13.75%	18.79%	20.33%
Interest Cost	0.37	0.77	0.37	1.96	3.41
Depreciation	3.19	4.12	4.31	5.04	7.21
Profit Before Tax (excl. Exceptional Items)	2.46	1.37	6.98	19.39	24.99
Profit After Tax	1.92	0.86	6.91	13.91	18.45
EPS	3.08	1.41	10.99	19.56	19.82

Balance Sheet Summary (Consolidated)

PARTICULARS (₹ IN CRORES)	FY19	FY20	FY21	FY22	FY23
Total Equity (Networth)	55.49	55.62	62.10	82.98	148.25
Non Current Liabilities	1.23	1.08	1.55	34.85	73.57
Current Liabilities	17.61	17.98	33.30	46.45	66.89
Total Equity and Liability	74.33	74.68	97.05	164.28	288.71
Non Current Assets	34.79	36.98	47.35	88.70	187.25
Current Assets	39.54	37.70	49.69	75.58	101.45
Total Assets	74.33	74.68	97.04	164.28	288.71

Cash Flow Statement Summary (Consolidated)

PARTICULARS (₹ IN CRORES)	FY19	FY20	FY21	FY22	FY23
Cash Flow from Operating Activities	2.09	6.90	5.78	1.16	15.53
Cash Flow from Investing Activities	(7.06)	(5.74)	(8.54)	(45.88)	(104.63)
Cash Flow from Financing Activities	4.28	(1.18)	2.52	46.02	89.17
Net increase/ (decrease) in cash and cash equivalents	(0.68)	(0.02)	(0.24)	1.30	0.08
Cash and cash equivalents at beginning of the year	0.74	0.05	0.33	0.10	1.40
Cash and cash equivalents at the end of the year	0.05	0.33	0.10	1.40	1.48

naturalcapsules.com

05

Investment Merits



Growth Drivers



Capacity enhancement with **state-of-the-art machinery** in capsules division, enabling operational efficiencies and driving profitability



Being the **only backward integrated manufacturer of steroidal APIs in India**, the Company plans to gain significant market share domestically



Exploring opportunities to set up capsules manufacturing facilities in foreign/domestic markets to ensure quick supply to customers



The Company will benefit from strong industry tailwinds on the back of the China Plus One strategy. This will further be amplified by robust government incentives (PLI scheme)



Focusing efforts on regulated markets and marquee pharma clients for capsules business, to stabilise its topline and enhance its margins



Strong focus on R&D will lead to the development of new products and processes, It will also enable operational efficiencies by increasing the yields of existing products



Regulatory approvals for the upcoming API facility will enable long term customer association leading to improved margins



Strategic Priorities

NCL is geared to bring about monumental changes in its approach towards its business. With the ongoing CAPEX, the Company is enabling itself to become the market leader in capsules business and positioning itself as a dominant player in the domestic steroidal API market.



STRATEGIC PRIORITY

- Positioning the business to reduce margin volatility
- Continue to grow sales of Capsules in regulated markets and expand global presence
- Introduce new variants of capsule products
- Develop new value-added molecules in steroidal and hormonal range of APIs
- Investing in technology and manufacturing processes to attain manufacturing efficiencies and competitive advantage
- API facility approved by regulatory bodies



ACTIONS TAKEN

- Collaborating with buyers who procure large quantities of capsules on a sustained basis
- Tying up with customers who sell finished formulations in regulated markets
- Sales and marketing team reaching out to new customers in new geographies
- Working on new varieties of capsules
- Strong focus on R&D will enable new products to be developed every 18 months
- Investing in R&D to further improve the output of capsule manufacturing machines
- Facility is being set up and quality management systems are being deployed to ensure compliance to the stringent requirements of the regulatory bodies



naturalcapsules.com

Thank You

CONTACT US

Natural Capsules Limited

TRIDENT TOWERS,
Fourth Floor, No. 23,
100 Feet Road, Jaynagar II Block,
Bangalore - 560 011, INDIA

FOR FURTHER INFORMATION, PLEASE CONTACT

Mrs. Shilpa Burman
COMPANY SECRETARY

Natural Capsules Limited
company.sec@naturalcapsules.com

Mr. Abhishek Mehra
INVESTOR RELATIONS ADVISOR
+91 95588 14500

TIL Advisors Private Limited
abhishek@theinvestmentlab.in